iEuroEwing

iEuroEwing is a Phase III international clinical trial to optimize treatment for Ewing sarcoma patients.

Agents: Systemic and local therapies
Phase III
Status Recruiting
Sponsor Co-funding of national funding bodies

 

Further information can be found here.

 

WHO is the trial for?
    • The trial is open for patients diagnosed with Ewing sarcoma or Ewing-like sarcoma of bone and/or soft tissue between 2 and 49 years of age.
    • The trial includes both patients with localized disease and with metastatic disease (spread to lungs, bones, or other sites).

WHAT is the key question that this trial is attempting to answer?

 This trial is designed to test whether combining standard treatments with vinorelbine and cyclophosphamide (VinoCyc) may lead to better outcomes for Ewing sarcoma patients. In patients with localized disease the trial will answer the question on an optimal radiation dose in standard risk Ewing Sarcoma.

  • Patients with local disease: The trial aims to see if adding a maintenance treatment (VinoCyc) to standard chemotherapy (vincristine, doxorubicin, cyclophsphamid (VDC) and ifosfamid, etoposide (IE)) improves event-free survival (EFS) in patients with localized Ewing sarcoma. It will also test if higher doses of radiation improve EFS without causing severe skin side effects.
  • Patients with metastatic disease: For patients with metastatic Ewing sarcoma, the trial will examine if adding VinoCyc to standard chemotherapy (VDC/IE) improves event-free survival (EFS).

WHY patients might want to participate?

 Participating in the iEuroEwing trial gives patients access to a promising new treatment approach that may improve outcomes for Ewing sarcoma, including both localized and metastatic disease. The study explores whether adding maintenance therapy (VinoCyc) and tailored radiation doses can increase survival rates. By joining, patients also help advance research that may benefit future patients. As with all trials, potential risks and benefits should be discussed with a doctor.

WHEN will the trial be open?

 The trial is actively recruiting participants.

WHERE is the trial available?

 The iEuroEwing trial is an international, multi-center study conducted across various European countries and other international sites. The study is currently open in the following countries:

Austria, Belgium, Finland, Germany, Greece, Hungary, Poland, Sweden for further information: https://euclinicaltrials.eu/search-for-clinical-trials/?lang=de&EUCT=2022-501180-40-00 

STUDY DESIGN: What does the study look like?

This Phase III international, randomized trial (iEuroEwing) evaluates treatment strategies for Ewing sarcoma patients, split into two groups:

  • Standard-Risk (SR): Cancer not spread

  • High-Risk (HR): Cancer has spread

Both groups receive standard chemotherapy and local treatment, but are randomized into:

  • Arm A: Standard treatment only

  • Arm B: Standard treatment plus maintenance therapy (Vinorelbine + Cyclophosphamide)

SR group also tests radiation dose levels across four risk-adapted strata, comparing standard RT with an additional 9 Gy.

Goals:

  • In SR, assess whether higher RT doses are not worse for skin toxicity.

  • In both SR and HR, evaluate if maintenance therapy improves event-free survival (EFS) by 10% (SR) or 17% (HR) over 2–3 years.

HOW do I get more information?

 Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients. If there are no such organisation in your country, please email us for more information: info@sarcoma-patients.org

SHARE your experience

   
You want to share your experience on this trial?
Send us an e-mail to: info@sarcoma-patients.org
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

  No results are available at this time. Future results will be linked here.

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.